drbio,
I'm sure it's a good question, but you've directed it at the dumbest guy on this board. Maybe more knowledgeable folks will chime in.
I did look at p.20-22 of the FDA briefing docs as you requested. My only question concerning your question is, "Why are you looking at the TEAE's (treatment emergent adverse effects) and comparing that to the pain issues?" Aren't they two totally different issues? I thought the TEAE's referred to the treatment effects of the chemotherapeutic agent, Satraplatin. I thought the pain issues referred to something else. Maybe I didn't understand your question. That's quite possible, since I don't know what i'm talking about.
Bladerunner
Market Data 
Markets 
AI
